Ascelia Pharma recently presented data from its Orviglance Hepatic Impairment study showing that Orviglance, a non-gadolinium oral contrast agent, has the potential to be used in patients with any degree of liver impairment. The data was presented during the June 14-16 European Society of Gastrointestinal and Abdominal Radiology (ESGAR), held in Valencia, Spain.